Clinical Trial Results

AstraZeneca

Research Sponsor:	AstraZeneca
Drugs Studied:	AZD2014
National Clinical Trial #:	NCT02640755
EudraCT#:	2015-000198-11
Protocol #:	D2270C00015
Study Date:	February 2016 to December 2016
Short Study Title:	A study to understand how the body processes AZD2014 in participants with advanced tumours when taken by itself or with other drugs

Thank you!

As a clinical study participant, you belong to a large community of participants around the world. You help researchers answer important health questions and discover new medical treatments.

Thank you for taking part in this clinical study for the drug AZD2014. This drug is being developed to treat cancer. You and all of the participants helped researchers learn how the body processes AZD2014 and if AZD2014 causes any medical problems.

AstraZeneca, the sponsor of this study, thanks you for your help and thinks it is important for you to know the results of your study. An independent non-profit organisation called CISCRP prepared this summary of the study results for you with the help of a medical writing organisation.

We hope it helps you understand and feel proud of your important role in medical research. If you have questions about the results, please speak with the study doctors or staff at your study site.

CISCRP
THE CENTER FOR INFORMATION & STUDY ON CLINICAL RESEARCH PARTICIPATION

What's happened since my study ended?

Your study started in February 2016 and ended in December 2016. The study included 4 participants at 1 study site in the United Kingdom. When the study ended, the sponsor reviewed the data and created a report of the results. This is a summary of that report.

Why was the research needed?

Before a new drug can be approved, research must be done to show that it is safe and effective. The study drug AZD2014 is being developed to treat advanced tumours. In healthy people, a protein called mTOR controls the growth and energy needs of cells. But this protein can become too active in people with cancer. This can make cells grow and multiply too much. Too much cell growth can create a tumour. AZD2014 blocks mTOR so that tumours cannot grow.

In this study, researchers wanted to see how the body reacts to AZD2014 treatment. In one participant in this study, researchers also looked at a drug called fulvestrant, another cancer drug that is already approved to treat tumours in the United Kingdom. Researchers studied the effects of AZD2014 when it was given as a solution to drink or tablets to swallow.

Researchers wanted to know:

- How much AZD2014 got into the blood and saliva, and how much AZD2014 left the body?
- How did tumours react to AZD2014 treatment?
- What medical problems did participants have after they took AZD2014?

What kind of study was this?

Your study was an "open-label" study. This means that all of the participants, study doctors, and staff knew what treatment each participant took. This study had 2 parts: Part 1 and Part 2. All participants participated in both parts.

Your study included 4 participants. All of the men and women who participated in this study were between 49 and 65 years of age.

What happened during the study?

You and the other participants who completed the study were in the study for about 5 months. All participants who participated in Part 1 went on to Part 2.

Before the study started, study doctors did a physical examination, including checking your height, weight, and heart health. They also measured your tumour and asked about your medical history, how you were feeling, and what medicines you were taking.

During Part 1, you took 1 dose of AZD2014 and stayed at the clinic for 8 days. In that time, study doctors took samples of your urine, faeces, saliva, vomit, and blood. The AZD2014 had a radioactive tag so that researchers could measure how much of the drug left your body through urine, faeces, saliva, and vomit.

During Part 2, you were assigned to 1 of 2 treatments:

- 50 mg of AZD2014 in tablets twice a day, continuously
- 125 mg of AZD2014 in tablets twice a day for 2 days in a row, followed by a 5 day rest, plus fulvestrant on Day 1 and Day 15 of the first treatment cycle and then monthly as an injection in the muscle

In Part 2, researchers measured how effective AZD2014 was and if AZD2014 was safe to use. You visited the clinic 4 times each month during Part 2.

Throughout the study, your study doctor examined you regularly. They did a physical examination, which included checking your height, weight, and heart health. They also measured your tumour and asked how you were feeling and what medicines you were taking.

The figure below shows how the study was done.

Open-label study: 4 participants



At the end of the study, study doctors did another physical examination, measured your tumour, and asked how you were feeling and what medicines you were taking.

What were the study results?

Below is a summary of the results of some of the questions the researchers asked during this study. It is important to know that researchers look at the results of many studies to decide which medicines work best and are safest for patients. Further clinical studies with AZD2014 are ongoing.

How much AZD2014 got into the blood and saliva, and how much AZD2014 left the body?

Researchers used blood and saliva samples to find out how much AZD2014 got into the blood and saliva of participants.

Researchers measured the following:

- Average amount of AZD2014 in the blood and saliva
- Highest amount of AZD2014 in the blood and saliva
- Time it took for AZD2014 to reach its highest amount in the blood and saliva
- The amount of AZD2014 that left the body

Average amount of AZD2014 in the blood and saliva

Researchers measured the average amount of AZD2014 in the blood and saliva in nanogram hours per millilitre of blood and saliva, or h•ng/mL. This is a way for researchers to measure the amount of drugs in blood and saliva. The chart below shows the average amount of the drug in the blood and saliva.



Highest amount of AZD2014 in the blood and saliva

Researchers measured the average highest amount of AZD2014 in the blood and saliva in nanograms per millilitre of blood or saliva, or ng/mL. This is a way for researchers to measure the highest amount of drugs in blood and saliva. The chart below shows the highest amount of the drug in the blood and saliva.



Time it took for AZD2014 to reach its highest amount in the blood and saliva

Researchers also measured the median amount of time in hours, or h, that it took for AZD2014 to reach its highest amount in the blood and saliva. The median is the amount of time halfway between the shortest time and the longest time it took for AZD2014 to reach its highest amount in the blood and saliva. The chart below shows this amount of time.



Amount of AZD2014 that left the body

The AZD2014 with a radioactive tag helped researchers measure the amount of AZD2014 that left the body through urine, faeces, saliva, and vomit. Researchers found the following:

- AZD2014 left the body mainly through the faeces about 72 hours.
- About 80.0% of the radioactive AZD2014 was found in the faeces, and about 12.0% was found in the urine.

How did tumours react to AZD2014 treatment?

Researchers also wanted to know how many participants had their tumours shrink or disappear after AZD2014 treatment. They also wanted to know how many participants had their disease stay the same or get worse. In this study, getting worse meant that tumours grew or spread to other areas. Researchers found the following:

- No participants had their tumours shrink or disappear.
- 100.0%, or all 3 of the participants who took AZD2014 alone, had their disease stay about the same.
- The 1 participant who took AZD2014 and fulvestrant had worsening of disease.

What medical problems did participants have after they took AZD2014?

A lot of research is needed to know whether a drug causes a medical problem, so researchers keep track of all medical problems that participants had during the study. These medical problems are called "adverse events". They may or may not be caused by the study drug.

How many participants had medical problems during the study?

During this study, all 4 participants (100%) had medical problems. No participants stopped study treatment because of medical problems. The table below shows how many participants in each treatment group had medical problems.

Medical problems during the study

	AZD2014 (out of 3 participants)	AZD2014 and fulvestrant (out of 1 participant)	Total (out of 4 participants)
How many participants had medical problems?	100.0% (3)	100.0% (1)	100.0% (4)

How many participants had serious medical problems?

A medical problem is considered serious when it is life threatening, causes lasting problems, or needs hospitalisation. No participants died during the study. Two participants developed serious medical problems during the study:

- 1 participant who took AZD2014 developed malaise, or feelings of general discomfort and uneasiness.
- 1 participant who took AZD2014 and fulvestrant developed urinary tract infections.

Study doctors did not consider these serious medical problems to be related to AZD2014 treatment.

What were the most common medical problems in the study?

Nausea and vomiting were the most common medical problems. The table below shows the medical problems that happened in at least 50% of participants in this study.

Most common medical problems in the study

Medical problem	AZD2014 (out of 3 participants)	AZD2014 and fulvestrant (out of 1 participant)	Total (out of 4 participants)
Nausea	66.7% (2)	100.0% (1)	75.0% (3)
Vomiting	66.7% (2)	100.0% (1)	75.0% (3)
Decrease in white blood cell count	33.3% (1)	100.0% (1)	50.0% (2)
Dry skin	66.7% (2)	0.0% (0)	50.0% (2)
Itchy skin	66.7% (2)	0.0% (0)	50.0% (2)
Low red blood cell count	33.3% (1)	100.0% (1)	50.0% (2)
Swelling and sores in the mouth	66.7% (2)	0.0% (0)	50.0% (2)
Swelling of the mucus membranes	33.3% (1)	100.0% (1)	50.0% (2)

Where can I learn more about the study?

If you have questions about the results, please speak with the study doctor or staff at your study site. You can find more information about your study online at www.clinicaltrials.gov/show/results/NCT02640755.

Official study title: A Phase 1, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [^{14}C] AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies

AstraZeneca AB, the sponsor of this study, has its headquarters in Södertälje, Sweden.

The phone number for the AstraZeneca Information Centre is 1-877-240-9479.

The results presented here are for a single study. Other studies may provide new information or different results. You should not make changes to your therapy based on the results of a single study without first consulting your healthcare professional.

Thank you

It is said that the greatest gift is one which is given anonymously, giving when you do not know whether you will get direct personal benefit.

This is the gift that you have given by taking part in a clinical study. It is a brave and selfless act, one that advances medical knowledge and benefits public health.

Thank you for the gift of your participation in clinical research.

CISCRP
THE CENTER FOR INFORMATION & STUDY ON CLINICAL RESEARCH PARTICIPATION

The Centre for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organisation focused on educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants for clinical studies, nor is it involved in conducting clinical studies.

CISCRP
One Liberty Square, Suite 510
Boston, MA 02109

1-877-MED-HERO
www.ciscrp.org